Tilray | TRLY - Cost Of Sales

Stock Price
7.55
Daily Change
-0.17 -2.20%
Monthly
-18.99%
Yearly
1,179.66%
Q2 Forecast
8.21

Tilray reported $164.37M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Akebia Therapeutics USD 10.34M 441K Dec/2025
Alaunos Therapeutics USD 0 18K Sep/2024
Aurora Cannabis CAD 88.61M 30.53M Dec/2025
Avita Medical AUD 3.3M 166K Dec/2025
Canopy Growth CAD 53.08M 8.3M Dec/2025
Cronos Group USD 28.74M 10.38M Dec/2025
Divis Laboratories Ltd INR 10.63B 1.23B Dec/2025
Ionis Pharmaceuticals USD 3M 5M Mar/2026
IQVIA Holdings USD 3.08B 161M Mar/2026
Knight Therapeutics CAD 82.22M 1.03M Dec/2025
Moderna USD 955M 503M Mar/2026
Organigram Holdings CAD 56.93M 20.53M Dec/2025
Organon & Co USD 766M 21M Dec/2025
Revvity USD 323.46M 26.93M Mar/2026
Tilray USD 164.37M 8.41M Sep/2025
Viatris USD 2.36B 195.9M Mar/2026
Xeris Pharmaceuticals USD 13.66M 49K Dec/2025
Zealand Pharma A/S 410K 5K Jun/2025